Economist Alvin Roth Discusses Ethics of Kidney Markets

Nobel-laureate economist Alvin Roth discussed the ethics and economics of buying and selling kidneys in a recent interview with host Bryan Walsh.

The debate centers on whether legalizing organ sales could solve critical medical shortages or if such markets are inherently immoral. This tension defines the concept of "repugnant markets," where certain goods are banned regardless of demand.

Roth examined the disparity between the legality of selling blood plasma and the strict prohibition of kidney sales. While plasma is a renewable resource, a kidney is a permanent organ, which creates a different moral and economic calculation for regulators.

Currently, tens of thousands ^[1] of Americans with end-stage kidney disease are waiting for a transplant. This high demand often leads to arguments that a paid market would increase the supply of available organs and save lives.

However, Roth challenged the notion that a lack of supply is the primary driver of the crisis. He said, "there's not really a shortage" ^[2]. This suggests that the problem may lie in the mechanisms of matching donors to recipients rather than a literal absence of kidneys.

Roth said that the ban on organ sales persists because society views the commodification of the human body as repugnant. These moral boundaries often override the economic logic of supply and demand, even when the result is a prolonged waiting list for patients.

The discussion highlighted that if a market were legalized, it could lead to the exploitation of the poor. Regulators fear that financial incentives would coerce vulnerable populations into risky surgeries, further complicating the ethical landscape of public health.